The Bottom Line
Retatrutide (commonly called “reta” in online communities) is a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors - one more receptor than tirzepatide’s (often called “tirz”) dual GIP/GLP-1 mechanism. In Phase 3 trials (TRIUMPH-1), retatrutide produced about 28.3% average weight loss at 12mg over 80 weeks, compared to tirzepatide’s 22.5% at 15mg over 72 weeks (both among people who stayed on treatment). The glucagon receptor adds an energy expenditure component that tirzepatide lacks, meaning your body actively burns more stored fat rather than relying solely on appetite suppression. Retatrutide is not FDA-approved and is still in clinical trials. Tirzepatide is FDA-approved and available as Mounjaro (diabetes) and Zepbound (weight loss). Use our free GLP-1 dose calculator to calculate doses for either compound.
The Core Difference: Two Receptors vs Three
Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. Tirzepatide (Mounjaro/Zepbound) is a dual agonist that activates only GLP-1 and GIP receptors, so retatrutide vs Mounjaro is the same comparison under a brand name. The addition of glucagon receptor activation is what sets retatrutide apart - it introduces a direct energy expenditure pathway that promotes fat oxidation and reduces hepatic fat independently of appetite suppression.
Think of it this way: semaglutide pulls one lever (appetite). Tirzepatide pulls two (appetite + fat metabolism). Retatrutide pulls all three (appetite + fat metabolism + energy expenditure). Each additional receptor doesn’t just add - it compounds the effect.
Pro Tip
The glucagon receptor is the reason retatrutide shows better fat-to-lean-mass loss ratios in early data. Glucagon signals the liver to break down stored fat for energy, which means more of the weight you lose comes from fat rather than muscle - a critical distinction for people who train.
Head-to-Head Weight Loss Comparison
| Metric | Retatrutide (12mg) | Tirzepatide (15mg) |
|---|---|---|
| Trial name | TRIUMPH-1 (Phase 3) | SURMOUNT-1 (Phase 3) |
| Duration | 80 weeks | 72 weeks |
| Average weight loss (people who stayed on treatment) | 28.3% / 70.3 lbs (31.9 kg) | 22.5% / ~52 lbs |
| Receptor targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP |
| FDA status | Phase 3 trials (not approved) | FDA approved |
| Developer | Eli Lilly | Eli Lilly |
The ~28.3% weight loss from TRIUMPH-1 at 80 weeks (people who stayed on treatment) is the highest ever recorded in an obesity drug trial. For context, semaglutide (Wegovy) averaged about 15% in its main trial, STEP-1, a figure that counts everyone who started treatment; counted the same way, retatrutide’s was 25.0%. Both retatrutide and tirzepatide are developed by Eli Lilly, and it’s expected that retatrutide will eventually be positioned as the next step up for patients who need more aggressive weight loss or have plateaued on tirzepatide.
Important
Retatrutide is currently in Phase 3 clinical trials and has not received FDA approval for any indication. The data presented here is from published clinical trial results (TRIUMPH-1, Phase 2 NEJM study). This comparison is for educational purposes only. Always work with a licensed healthcare provider for treatment decisions.
Mechanism of Action Breakdown
| Receptor | What It Does | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|---|
| GLP-1 | Reduces appetite, slows gastric emptying, improves insulin sensitivity | ✓ | ✓ | ✓ |
| GIP | Enhances fat metabolism, works synergistically with GLP-1 signaling | — | ✓ | ✓ |
| Glucagon | Increases energy expenditure, promotes hepatic fat oxidation, raises metabolic rate | — | — | ✓ |
GLP-1 makes you eat less. GIP helps your body process fat more efficiently. Glucagon makes your body burn more energy even at rest. Tirzepatide gives you the first two. Retatrutide gives you all three - which is why it produces more weight loss with potentially better preservation of lean muscle mass. For the published fat loss vs muscle retention data, see the retatrutide body recomposition guide.
Community Insight
Users who have tried both compounds frequently report that the appetite suppression from reta feels “sharper” than tirz, and that they notice increased body heat - particularly after meals. This is consistent with glucagon receptor activation increasing thermogenesis. The common description is “you feel like your metabolism is running hotter.” This is anecdotal and varies by individual.
Side Effects Comparison
| Side Effect | Tirzepatide | Retatrutide |
|---|---|---|
| Nausea | Common (especially during titration) | Common (more pronounced at 8mg+) |
| Decreased appetite | Very common | Very common (stronger) |
| Diarrhea | Common | Common |
| Constipation | Common | Common |
| Injection site reactions | Occasional | More common than tirzepatide |
| Vomiting | Occasional | Occasional (more common at higher doses) |
| Elevated heart rate | Small increase (on label) | Occasional (rises with the dose, Phase 2) |
| Fatigue | Occasional | Occasional (more common in first 2 weeks at each dose) |
The glucagon receptor activation in retatrutide produces a somewhat different side effect profile. Heart rate rises on both drugs. With retatrutide the Phase 2 trial saw a dose-dependent rise that peaked at 24 weeks and declined after that.
Pro Tip
Many users manage retatrutide’s stronger nausea by splitting their weekly dose into two injections (e.g., 3mg Monday + 3mg Thursday instead of 6mg once weekly). This “microdosing” approach smooths out blood levels and reduces the nausea spike that comes 24-48 hours after a full weekly injection. Use our split-dose calculator to calculate the exact units for each injection.
Cost and Access
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Brand-name (US) | List $1,087/month; $299-699 self-pay (Zepbound, LillyDirect) | Not available (not approved) |
| Insurance coverage | Possible (FDA-approved) | Not covered (investigational) |
| Regulated access | Widely available via prescription | Clinical trials only |
US dollars, Lilly pages, last checked October 2026. Detail by dose: how to get a GLP-1 in the US.
Tirzepatide has the significant advantage of FDA approval, which means insurance coverage is possible and the supply chain is regulated. Retatrutide has neither: it isn’t approved anywhere, so there is no insurance coverage and no regulated supply. If cost and access matter to you, tirzepatide is the practical choice today.
Switching from Tirzepatide to Retatrutide
“I’ve plateaued on tirzepatide - should I switch to retatrutide?” This is one of the most common questions in the GLP-1 community right now.
When Switching Makes Sense
- You’ve been on maximum tirzepatide dose (15mg) for 8+ weeks with stalled weight loss
- You’ve optimized diet, protein intake, and exercise and still plateaued
- You’re working with a provider who can monitor your transition
Our dedicated switching guide covers how to actually make the switch week by week, including the gap week and the 2mg start.
The Switching Protocol (Community-Sourced)
| Step | Action |
|---|---|
| Week 0 | Take your last tirzepatide dose |
| Week 1 | Skip (gap week - both compounds have ~5-6 day half-lives) |
| Week 2 | Start retatrutide at 2mg regardless of your previous tirzepatide dose |
| Weeks 3-5 | Stay at 2mg - assess GI tolerance to the glucagon receptor |
| Week 6+ | Titrate up to 4mg, then follow standard titration (4 to 6 to 8 to 12mg every 4 weeks) |
Important
There is no established medical conversion protocol for switching from tirzepatide to retatrutide, as retatrutide is not FDA-approved and no switching studies have been published. The protocol above is based on community experience and provider guidance. Always start retatrutide at 2mg regardless of your previous tirzepatide dose - the glucagon receptor activation introduces pharmacological effects your body has not been exposed to.
Community Insight
Users who switched from tirz to reta commonly report breaking through weight loss plateaus within 2-3 weeks. The most frequently mentioned effect is the return of strong appetite suppression that had faded on tirzepatide, plus a noticeable increase in energy and body heat - consistent with the added glucagon mechanism. Some users describe it as “feeling like when you first started tirzepatide, but stronger.”
Which One Should You Choose?
Choose Tirzepatide If:
- You want an FDA-approved, insurance-coverable medication
- You’re starting your first GLP-1 compound
- You prefer a well-established safety profile with years of real-world data
- Your BMI is 30-40 and you’re looking for 15-22% weight loss
- Cost and accessibility are important factors
Choose Retatrutide If:
- You’ve plateaued on tirzepatide or semaglutide
- You have a BMI of 40+ and need maximum weight loss
- You’re comfortable using an investigational compound under provider supervision
- You specifically want the energy expenditure benefits of glucagon activation
- Muscle preservation during fat loss is a priority (e.g., you train regularly)
Regimen tracks both. Whether you’re on tirzepatide, retatrutide, or transitioning between them, track your doses, weight, side effects, and blood levels in one place. Compare your protocols
Tracking Your Protocol
Whether you’re sticking with tirzepatide or switching to retatrutide, tracking matters. Log every dose, track your weight trend, note side effects at each dose tier, and share your data with your provider. The Regimen app supports both compounds, with one estimated medication-level curve per compound, so you can see roughly where each level peaks and troughs through the week.
Related: Retatrutide Tracker | Tirzepatide Tracker | GLP-1 Dose Calculator | Split Dose Calculator
Deeper reads: Best Peptides for Fat Loss in 2026 | Body Recomposition with Peptides
Frequently Asked Questions
Is retatrutide FDA-approved?
No. Retatrutide is still in clinical trials (Lilly’s TRIUMPH program). It has not been approved by the FDA for weight loss or diabetes.
Can I switch from tirzepatide to retatrutide?
There are no established switching protocols because retatrutide isn’t approved. Most providers suggest finishing your current tirzepatide cycle, waiting 1-2 weeks, then starting retatrutide at the lowest dose.
Is retatrutide stronger than tirzepatide?
On weight loss, the trials point that way: in separate Phase 3 trials, retatrutide 12 mg averaged about 28.3% over 80 weeks (TRIUMPH-1) and tirzepatide 15 mg averaged 22.5% over 72 weeks (SURMOUNT-1); both figures count people who stayed on treatment. Those were different trials, so it isn’t a head-to-head result; the head-to-head trial (TRIUMPH-5) finishes in late 2026.
Is retatrutide stronger than Mounjaro?
Mounjaro is tirzepatide, so retatrutide vs Mounjaro comes down to the retatrutide vs tirzepatide numbers on this page. The difference: Mounjaro is approved; retatrutide is not approved anywhere.
What are the side effects of retatrutide vs tirzepatide?
Both share GI side effects. Retatrutide’s glucagon component may cause increased heart rate and potential blood sugar fluctuations. Phase 2 data showed similar tolerability profiles.
How much does retatrutide cost compared to tirzepatide?
Retatrutide isn’t approved anywhere, so it has no list price, no insurance coverage and no regulated supply, and we don’t list prices for what’s sold online. Tirzepatide is FDA-approved as Mounjaro and Zepbound, and what you pay depends on your insurance and pharmacy.
Can I track retatrutide in a peptide tracker app?
Yes. Regimen supports retatrutide with medication level modeling, dose logging, and health metric correlation alongside other compounds.
Disclaimer: This article is for educational purposes only and is not medical advice. Retatrutide is not FDA-approved and is currently in Phase 3 clinical trials. Never switch medications without consulting your prescriber. Individual responses to these medications vary significantly.
Ready to track your GLP-1?
- Smart reminders so you never miss a dose
- Track weight, photos, and progress over time
- Medication level curves for 150+ compounds
Can I take retatrutide and tirzepatide together?
No, not at the same time. Retatrutide works on the same two receptors as tirzepatide, plus a third, so taking both mostly adds side effects, with no evidence of extra weight loss. Some overlap while you switch is normal, since tirzepatide stays in your body for weeks after your last shot. Our switching guide covers the timing.
When will retatrutide be FDA approved?
Retatrutide is still in Phase 3 trials (Lilly’s TRIUMPH program). TRIUMPH-1, the main obesity trial, reported in May 2026, and TRIUMPH-2 and TRIUMPH-3 in July. Lilly has said it will file for FDA approval in the first quarter of 2027, so a decision would come after that. Until then, the only regulated access is through a clinical trial.
How much does compounded retatrutide cost?
There is no approved or regulated version of retatrutide to price, compounded or otherwise: it is still in Phase 3 trials and not approved anywhere, so we don’t list prices for what’s sold online. Brand-name tirzepatide (Mounjaro, Zepbound) is FDA-approved and may be partly covered by insurance.
Does retatrutide cause more muscle loss than tirzepatide?
Early data suggests the opposite, retatrutide may preserve lean mass slightly better than tirzepatide during weight loss. The glucagon receptor activation promotes preferential fat oxidation, meaning more of the weight lost comes from fat rather than muscle. However, this needs confirmation in larger studies. Regardless of which compound you use, maintaining adequate protein intake (1.2-1.6g/kg/day) and resistance training are the most important factors for preserving muscle during GLP-1-mediated weight loss.
What’s the difference between retatrutide and semaglutide?
Semaglutide targets one receptor (GLP-1). Retatrutide targets three (GLP-1, GIP, and glucagon). In their main obesity trials, counting everyone who started treatment, semaglutide averaged about 15% weight loss (STEP-1) and retatrutide 25.0% (TRIUMPH-1). Semaglutide is FDA-approved with years of real-world safety data. Retatrutide is investigational. For a full three-way comparison, see the mechanism table in this article.
![]()